Metallothionein-I and -III expression in animal models of Alzheimer disease

Neuroscience

Volumn 143, Issue 4, 2006, Pages 911-922

  Carrasco, J ^a   Adlard, P ^b,c   Cotman, C ^c   Quintana, A ^a   Penkowa, M ^d   Xu, F ^e   Van Nostrand, W E ^e   Hidalgo, J ^a  

^a Institute of Neuroscience   (Spain)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Faculty of Health Sciences   (Denmark)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; metallothionein I; metallothionein III; Tg2576; TgCRND8; TgSwDI

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CONGO RED; GREEN FLUORESCENT PROTEIN; ISOPROTEIN; MESSENGER RNA; METALLOTHIONEIN I; METALLOTHIONEIN II;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MACROPHAGE; MALE; MICROGLIA; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; BRAIN; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; MALE; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MUTATION; NERVE TISSUE PROTEINS; RNA, MESSENGER; SENILE PLAQUES;

EID: 33751546646     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.08.054     Document Type: Article

References (69)

1. Adlard P.A., Perreau V.M., Pop V., and Cotman C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 25 (2005) 4217-4221
2. Adlard P.A., West A.K., and Vickers J.C. Increased density of metallothionein I/II-immunopositive cortical glial cells in the early stages of Alzheimer's disease. Neurobiol Dis 5 (1998) 349-356
3. Amoureux M.C., Van Gool D., Herrero M.T., Dom R., Colpaert F.C., and Pauwels P.J. Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired. Mol Chem Neuropathol 32 (1997) 101-121
4. Andrews G.K. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 59 (2000) 95-104
5. Arai Y., Uchida Y., and Takashima S. Developmental immunohistochemistry of growth inhibitory factor in normal brains and brains of patients with Down syndrome. Pediatr Neurol 17 (1997) 134-138
6. Asanuma M., Miyazaki I., Higashi Y., Tanaka K., Haque M.E., Fujita N., and Ogawa N. Aggravation of 6-hydroxydopamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain. Neurosci Lett 327 (2002) 61-65
7. Blaauwgeers H.G., Anwar Chand M., van den Berg F.M., Vianney de Jong J.M., and Troost D. Expression of different metallothionein messenger ribonucleic acids in motor cortex, spinal cord and liver from patients with amyotrophic lateral sclerosis. J Neurol Sci 142 (1996) 39-44
8. Carrasco J., Giralt M., Molinero A., Penkowa M., Moos T., and Hidalgo J. Metallothionein (MT)-III: generation of polyclonal antibodies, comparison with MT-I+II in the freeze lesioned rat brain and in a bioassay with astrocytes, and analysis of Alzheimer' s disease brains. J Neurotrauma 16 (1999) 1115-1129
9. Carrasco J., Giralt M., Penkowa M., Stalder A.K., Campbell I.L., and Hidalgo J. Metallothioneins are upregulated in symptomatic mice with astrocyte-targeted expression of tumor necrosis factor-α. Exp Neurol 163 (2000) 46-54
10. Carrasco J., Penkowa M., Hadberg H., Molinero A., and Hidalgo J. Enhanced seizures and hippocampal neurodegeneration following kainic acid induced seizures in metallothionein-I+II deficient mice. Eur J Neurosci 12 (2000) 2311-2322
11. Carrasco J., Hernández J., Bluethmann H., and Hidalgo J. Interleukin-6 and tumor necrosis factor-alpha type 1 receptor deficient mice reveal a role of IL-6 and TNF-alpha on brain metallothionein-I and -III regulation. Mol Brain Res 57 (1998) 221-234
12. Carrasco J., Hernández J., González B., Campbell I.L., and Hidalgo J. Localization of metallothionein-I and -III expression in the CNS of transgenic mice with astrocyte-targeted expression of interleukin 6. Exp Neurol 153 (1998) 184-194
13. Carrasco J., Penkowa M., Giralt M., Camats J., Molinero A., Campbell I.L., Palmiter R.D., and Hidalgo J. Role of metallothionein-III following central nervous system damage. Neurobiol Dis 13 (2003) 22-36
14. Ceballos D., Lago N., Verdu E., Penkowa M., Carrasco J., Navarro X., Palmiter R.D., and Hidalgo J. Role of metallothioneins in peripheral nerve function and regeneration. Cell Mol Life Sci 60 (2003) 1209-1216
15. Chisthi M., Yang D., Janus C., Phinney A., Home P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morrissette C., Paquette J., Gervais F., Bergeron C., Fraser P., Carlson G., George-Hyslop P., and Westeway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276 (2001) 21562-21570
16. Chuah M.I., and Getchell M.L. Metallothionein in olfactory mucosa of Alzheimer's disease patients and apoE-deficient mice. Neuroreport 10 (1999) 1919-1924
17. Davis J., Xu F., Deane R., Romanov G., Previti M., Zeigler K., and Zlokovic B van Nostrand W. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem. 279 (2004) 20296-20306
18. DeMattos R.B., O'dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., Paul S.M., Aronow B.J., and Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 99 (2002) 10843-10848
19. Dudal S., Krzywkowski P., Paquette J., Morissette C., Lacombe D., Tremblay P., and Gervais F. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging 25 (2004) 861-871
20. Duguid J.R., Bohmont C.W., Liu N.G., and Tourtellotte W.W. Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc Natl Acad Sci U S A 86 (1989) 7260-7264
21. Erickson J.C., Hollopeter G., Thomas S.A., Froelick G.J., and Palmiter R.D. Disruption of the metallothionein-III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 17 (1997) 1271-1281
22. Erickson J.C., Sewell A.K., Jensen L.T., Winge D.R., and Palmiter R.D. Enhanced neurotrophic activity in Alzheimer's disease cortex is not associated with down-regulation of metallothionein-III (GIF). Brain Res 649 (1994) 297-304
23. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Muckestar L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., and Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
24. Gasull T., Giralt M., Hernández J., Martínez P., Bremner I., and Hidalgo J. Regulation of metallothionein concentrations in rat brain: effect of glucocorticoids, zinc, copper, and endotoxin. Am J Physiol 266 (1994) E760-E767
25. Gasull T., Rebollo D.V., Romero B., and Hidalgo J. Development of a competitive double antibody radioimmunoassay for rat metallothionein. J Immunoassay 14 (1993) 209-225
26. Giralt M., Penkowa M., Hernández J., Molinero A., Carrasco J., Lago N., Camats J., Campbell I.L., and Hidalgo J. Metallothionein-1+2 deficiency increases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. Neurobiol Dis 9 (2002) 319-338
27. Giralt M., Penkowa M., Lago N., Molinero A., and Hidalgo J. Metallothionein-1+2 protect the CNS after a focal brain injury. Exp Neurol 173 (2002) 114-128
28. Hidalgo J., Aschner M., Zatta P., and Vasák M. Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 55 (2001) 133-145
29. Hidalgo J., Belloso E., Hernández J., Gasull T., and Molinero A. Role of glucocorticoids on rat brain metallothionein-I and -III response to stress. Stress 1 (1997) 231-240
30. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
31. Huang X., Cuajungco M.P., Atwood C.S., Moir R.D., Tanzi R.E., and Bush A.I. Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 130 (2000) 1488S-1493S
32. Isumi H., Uchida Y., Hayashi T., Furukawa S., and Takashima S. Neuron death and glial response in pontosubicular necrosis. The role of the growth inhibition factor. Clin Neuropathol 19 (2000) 77-84
33. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., and McConlogue L. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 94 (1997) 1550-1555
34. Kawashima T., Doh-ura K., Torisu M., Uchida Y., Furuta A., and Iwaki T. Differential expression of metallothioneins in human prion diseases. Dement Geriatr Cogn Disord 11 (2000) 251-262
35. Kramer K.K., Liu J., Choudhuri S., and Klaassen C.D. Induction of metallothionein mRNA and protein in murine astrocyte cultures. Toxicol Appl Pharmacol 136 (1996) 94-100
36. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500-508
37. Martin B.l., Tokhein A.M., McCarthy P.T., Doms B.S., Davis A.A., and Armitage I.M. Metallothionein-3 and neuronal nitric oxide synthase levels in brains from the Tg2576 mouse model of Alzheimer's disease. Mol Cell Biochem 238 (2006) 129-137
38. Masters B.A., Quaife C.J., Erickson J.C., Kelly E.J., Froelick G.J., Zambrowicz B.P., Brinster R.L., and Palmiter R.D. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 14 (1994) 5844-5857
39. Miao J., Xu F., Davis J., Otte-Holler I., Verbeek M.M., and Van Nostrand W.E. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol 167 (2005) 505-515
40. Miyazaki I., Asanuma M., Higashi Y., Sogawa C.A., Tanaka K., and Ogawa N. Age-related changes in expression of metallothionein-III in rat brain. Neurosci Res 43 (2002) 323-333
41. Molinero A., Penkowa M., Hernández J., Camats J., Giralt M., Lago N., Carrasco J., Campbell I.L., and Hidalgo J. Metallothionein-I overexpression decreases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. J Neuropathol Exp Neurol 62 (2003) 315-328
42. Nagano S., Satoh M., Sumi H., Fujimura H., Tohyama C., Yanagihara T., and Sakoda S. Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur J Neurosci 13 (2001) 1363-1370
43. Palmiter R.D., Findley S.D., Whitmore T.E., and Durnam D.M. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A 89 (1992) 6333-6337
44. Penkowa M., Camats J., Giralt M., Molinero A., Hernández J., Carrasco J., Campbell I.L., and Hidalgo J. Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression. Glia 42 (2003) 287-306
45. Penkowa M., Espejo C., Martínez-Cáceres E.M., Montalban X., and Hidalgo J. Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis. Cell Mol Life Sci 60 (2003) 185-197
46. Penkowa M., Espejo C., Ortega-Aznar A., Hidalgo J., Montalban X., and Martínez-Cáceres E.M. Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci 60 (2003) 1258-1266
47. Penkowa M., Carrasco J., Giralt M., Molinero A., Hernández J., Campbell I.L., and Hidalgo J. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J Cereb Blood Flow Metab 20 (2000) 1174-1189
48. Penkowa M., Carrasco J., Giralt M., Moos T., and Hidalgo J. CNS wound healing is severely depressed in metallothionein I- and II-deficient mice. J Neurosci 19 (1999) 2535-2545
49. Penkowa M., Moos T., Carrasco J., Hadberg H., Molinero A., Bluethmann H., and Hidalgo J. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia 25 (1999) 343-357
50. Penkowa M., Espejo C., Martínez-Cáceres E.M., Poulsen C.B., Montalban X., and Hidalgo J. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J Neuroimmunol 119 (2001) 248-260
51. Puttaparthi K., Gitomer W.L., Krishnan U., Son M., Rajendran B., and Elliott J.L. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J Neurosci 22 (2002) 8790-8796
52. Quaife C.J., Findley S.D., Erickson J.C., Froelick G.J., Kelly E.J., Zambrowicz B.P., and Palmiter R.D. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33 (1994) 7250-7259
53. Quon D., Wang Y., Catalano R., Scardina J.M., Murakami K., and Cordell B. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352 (1991) 239-241
54. Searle P.F., Davison B.L., Stuart G.W., Wilkie T.M., Norstedt G., and Palmiter R.D. Regulation, linkage, and sequence of mouse metallothionein I and II genes. Mol Cell Biol 4 (1984) 1221-1230
55. Sillevis Smitt P.A., Blaauwgeers H.G., Troost D., and de Jong J.M. Metallothionein immunoreactivity is increased in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett 144 (1992) 107-110
56. Sillevis Smitt P.A., Mulder T.P., Verspaget H.W., Blaauwgeers H.G., Troost D., and de Jong J.M. Metallothionein in amyotrophic lateral sclerosis. Biol Signals 3 (1994) 193-197
57. Streit W.J. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77 (2004) 1-8
58. Sturchler-Pierrat C., and Sommer B. Transgenic animals in Alzheimer's disease research. Rev Neurosci 10 (1999) 15-24
59. Trendelenburg G., Prass K., Priller J., Kapinya K., Polley A., Muselmann C., Ruscher K., Kannbley U., Schmitt A.O., Castell S., Wiegand F., Meisel A., Rosenthal A., and Dirnagl U. Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J Neurosci 22 (2002) 5879-5888
60. Tsuji S., Kobayashi H., Uchida Y., Ihara Y., and Miyatake T. Molecular cloning of human growth inhibitory factor cDNA and its down-regulation in Alzheimer's disease. EMBO J 11 (1992) 4843-4850
61. Uchida Y. Growth inhibitory factor in brain. In: Suzuki K.T., et al. (Ed). Metallothionein III (1993), Birkhäuser Verlag, Basel 315-328
62. Uchida Y. Growth-inhibitory factor, metallothionein-like protein, and neurodegenerative diseases. Biol Signals 3 (1994) 211-215
63. Uchida Y., Takio K., Titani K., Ihara Y., and Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 7 (1991) 337-347
64. van Lookeren Campagneqq M., Thibodeaux H., van Bruggen N., Cairns B., Gerlai R., Palmer J.T., Williams S.P., and Lowe D.G. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci U S A 96 (1999) 12870-12875
65. van Lookeren Campagneqq M., Thiobodeaux H., van Bruggen N., Cairns B., and Lowe D.G. Increased binding activity at an antioxidant-responsive element in the metallothionein-1 promoter and rapid induction of metallothionein-1 and -2 in response to cerebral ischemia and reperfusion. J Neurosci 20 (2000) 5200-5207
66. Yagle M.K., and Palmiter R.D. Coordinate regulation of mouse metallothionein I and II genes by heavy metals and glucocorticoids. Mol Cell Biol 5 (1985) 291-294
67. Yu W.H., Lukiw W.J., Bergeron C., Niznik H.B., and Fraser P.E. Metallothionein III is reduced in Alzheimer's disease. Brain Res 894 (2001) 37-45
68. Zambenedetti P., Giordano R., and Zatta P. Metallothioneins are highly expressed in astrocytes and microcapillaries in Alzheimer's disease. J Chem Neuroanat 15 (1998) 21-26
69. Zheng H., Berman N.E., and Klaassen C.D. Chemical modulation of metallothionein I and III mRNA in mouse brain. Neurochem Int 27 (1995) 43-58